are extrahepatic cholangiocarcinomas, the second edition of the ICD-O (ICD-O-2) assigned them a histology code 8162/3, Klatskin, which was cross-referenced to intrahepatic cholangiocarcinoma. Recent studies in the United States that included this code (8162/3, Klatskin) with intrahepatic cholangiocarcinoma reported an increasing incidence of intrahepatic cholangiocarcinoma and a decreasing incidence of extrahepatic cholangiocarcinoma. To investigate the impact of this misclassifi cation on site-specifi c cholangiocarcinoma incidence rates, we calculated annual percent changes (APCs) with data from the Surveillance, Epidemiology, and End Results (SEER) program using a Poisson regression model that was age-adjusted to the year 2000 U.S. population. All statistical tests were two-sided. During 1992 -2000, when SEER used ICD-O-2, 1710 intrahepatic cholangiocarcinomas, 1371 extrahepatic cholangiocarcinomas, and 269 hilar cholangiocarcinomas identifi ed by code 8162/3, Klatskin were diagnosed. Ninety-one percent (246 of 269 ) of the hilar cholangiocarcinomas were incorrectly coded as intrahepatic cholangiocarcinomas, resulting in an overestimation of intrahepatic cholangiocarcinoma incidence by 13% and underestimation of extrahepatic cholangiocarcinomas incidence by 15%. However, even after the exclusion of tumors that were coded to the histology code 8162/3, Klatskin, ageadjusted annual intrahepatic cholangiocarcinoma incidence increased during this period (APC = 4%, 95% confi dence interval = 2% to 6%,
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. These tumors have distinct clinical and biologic features ( 5 , 6 ) . In Version 1 of ICD-O (ICD-O-1, ( 7 ) ), hilar cholangiocarcinomas were not assigned a unique ICD-O code and may have been coded as either intra-or extrahepatic cholangiocarcinomas. In ICD-O-2, hilar cholangiocarcinomas were assigned a unique histology code (8162/3, Klatksin), rather than a topography code, which was cross-referenced to the topography code for intrahepatic rather than extrahepatic cholangiocarcinomas ( 8 ) . Furthermore, hilar cholangiocarcinomas could also be correctly reported as extrahepatic cholangiocar cinomas using other histology codes. In the year 2000, ICD-O-3 ( 4 ) cross-referenced hilar cholangiocarcinoma to topography codes for either intrahepatic or extrahepatic cholangiocarcinomas. Thus, hilar cholangiocarcinomas may have mistakenly been classifi ed as intrahepatic cholangiocarcinomas under all versions of ICD-O, although misclassifi cation seems particularly likely under ICD-O-2.
Recent studies in the United States have reported an increasing incidence of primary liver cancer, including intrahepatic cholangiocarcinoma ( 9 ) and suggest a decreasing incidence of extrahepatic cholangiocarcinoma ( 10 ) . Given that hilar cholangiocarcinomas are thought to be the most common cholangiocarcinomas ( 11 ) and were likely misclassifi ed as intrahepatic cholangiocarcinomas under ICD-O-2, cholangiocarcinoma incidence may have been misreported. To investigate this hypothesis, we examined the classification of hilar cholangiocarcinomas reported as code 8162/3 and its impact on intrahepatic and extrahepatic cholangiocarcinoma incidence rates using population-based data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) cancer registry program ( 12 ) .
Intrahepatic and extrahepatic cholangiocarcinoma incidence rates from nine SEER registries (Atlanta, Connecticut, standard population. Relative risks and corresponding annual percent changes (APCs) with 95% confi dence intervals (CIs) for the Poisson models were computed (SAS Version 9.1; SAS Institute, Cary, NC). All tests of statistical signifi cance and confi dence intervals were two-sided. P <.05 was considered statistically signifi cant.
Between 1992 and 2000, 3350 cholangiocarcinomas were diagnosed and reported to SEER, of which 1710 (51%) were intrahepatic cholangiocarcinoma and 1640 were extrahepatic tumors (49%). Of the 1640 extrahepatic tumors, 1371 (84%) were reported as extrahepatic cholangiocarcinoma and 269 (16%) were reported as hilar cholangiocarcinomas under code 8162/3. Ninety-one percent (246 of 269) of the hilar cholangiocarcinomas were reported as intrahepatic cholangiocarcinomas. For the years 2001 and 2002, 54% (22 of 41) of the hilar cholangiocarcinomas reported under code 8162/3 were coded as intrahepatic cholangiocarcinomas.
We calculated the age-adjusted incidence trends for intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma ( Fig. 2 ) . Between 1992 and 2000, the incidence of intrahepatic cholangiocarcinoma (excluding hilar cholangiocarcinoma) increased (APC = 4%, 95% CI = 2% to 6%; P <.001). The incidence of extrahepatic cholangiocarcinoma (including code 8162/3) remained constant (APC = 1%, 95% CI = − 1% to 3%; P = .33).
Trends in incidence of hilar cholangiocarcinoma reported under code 8162/3 were similar to the overall incidence trends of extrahepatic cholangiocarcinoma (APC = 1%, 95% CI = − 4% to 6%; P = .6). Between 1973 and 1991, the increase in incidence of intrahepatic cholangiocarcinoma was similar to that for the time period 1992 -2000 (APC = 5%, 95% CI = 4% to 6%; P <.001). However, there was a 1% per year decrease in extrahepatic cholangiocarcinoma incidence (APC = − 1%, 95% CI = − 2% to 0%; P = .05).
These data indicate that the current coding of cholangiocarcinomas, particularly hilar cholangiocarcinoma, is problematic for several reasons. It has caused substantial misclassifi cation of extrahepatic as intrahepatic cholangiocarcinomas, which has resulted in overreporting of intrahepatic cholangiocarcinomas by 13% and underreporting of extrahepatic 1.200 1 9 7 3 1 9 7 5 1 9 7 7 1 9 7 9 1 9 8 1 1 9 8 3 1 9 8 5 1 9 8 7 1 9 8 9 1 9 9 1 1 9 9 3 1 9 9 5 1 9 9 7 1 9 9 9 2 0 0 1 In summary, the ICD-O-2 coding for hilar cholangiocarcinoma introduced some error in the reporting of cholangiocarcinoma rates in SEER between 1992 and 2000. The validity of our fi ndings also depends, of course, on the completeness and accuracy of the reported registry data. In ICD-O-3, this problem has only partially been addressed by cross-referencing the hilar cholangiocarcinoma histology code 8162/3 to topographies for both intra hepatic and extrahepatic cholangiocarcinoma. We recommend that, in the future, hilar cholangiocarcinoma be assigned a unique topography code listed as a subsite of extrahepatic cholangio carcinoma, under consideration of other parts of the extrahepatic bile duct. Accurate classifi cation of hilar cholangiocarcinoma would improve the ability to monitor incidence trends of intrahepatic and extrahepatic cholangiocarcinoma and would enhance the ability of studies to examine the etiology of these tumors. In addition, from a clinical and public health perspective, an appropriate, unambiguous coding of hilar cholangiocarcinomas is becoming in creasingly more important as more options for therapies, including liver transplantation, are being considered ( 15 -17 ) . The possibility of monitoring and eva luating therapeutic approaches, therapyrelated morbidity, mortality, and survival in tumor databases would be greatly enhanced by the addition of a hilar cholangiocarcinoma-specifi c topography code.
